Rhinomed Ltd (ASX:RNO) Investor update August 2022

INVESTOR UPDATE

August 2022

AUGUST 2022

IMPORTANT NOTICE

The information contained in this presentation (Presentation) has been prepared by Rhinomed Limited ACN 107 903 159 (Rhinomed).

This Presentation provides general background information about Rhinomed which is current at the date this Presentation.is made. This Presentation is not a prospectus, product disclosure statement or any other

offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission (ASIC)) or any other law and does not require all material information which a prospective investor may require in evaluating a possible investment in Rhinomed. This Presentation is for information purposes only and is not an invitation to acquire or offer of securities for subscription, purchase or sale in any

jurisdiction.

The information contained in this Presentation does not constitute financial advice and is not intended to be relied upon as advice to investors or potential investors. The information contained in this Presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Information in this Presentation remains subject to change without notice.

While the information contained herein has been prepared in good faith, neither Rhinomed nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give,

any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as Information) and liability therefore is expressly disclaimed. Accordingly, neither Rhinomed nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

This Presentation may contain forward-looking statements about Rhinomed's financial results, guidance and/or business prospects that may involve risks or uncertainties and may involve significant items of

subjective judgement and assumptions of future events that may or may not eventuate. Such items include Government policy changes, changes in the competitive environment, loss of contracts and unexpected changes to business costs or expenses. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. No representation or warranty is given as to the accuracy or likelihood of achievement of any forward-looking statement in this Presentation, or any events or results expressed or implied in any forward-looking statement.

This Presentation should not be considered as the giving of investment advice by Rhinomed or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of Rhinomed after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

In particular, this Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or to or for the account or benefit of any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act")). The securities to be offered as part of the Transaction have not been, and will not be, registered under the U.S. Securities Act. Securities may not be

offered or sold in the United States or to, or for the account or benefit of, any U.S. person, unless the securities have been registered under the U.S. Securities Act or an exemption from registration is available.

Neither the information contained in this Presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed, in whole or in part, in any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the applicable securities laws. The recipient in any jurisdiction where distribution of this Presentation is

prohibited or restricted must inform itself of, and comply with, any such prohibitions or restrictions. If the recipient is in any doubt about any of the contents of this Presentation, it should obtain independent

professional advice. The recipient represents that it is able to receive this Presentation without contravention of any unfulfilled registration requirements or other legal restrictions in the jurisdiction in which it resides or conducts its business. By receiving and retaining the Presentation, the recipient acknowledges that it will be solely responsible for its own assessment of the market and the market position of Rhinomed and is subsidiaries

(the Group) and that it will conduct its own analysis and be solely responsible for forming its own view of the potential future performance of the business of the Group.

All references to currency are to Australian currency, unless otherwise indicated

COMPANY SNAPSHOT

COMMERCIALISING A PROPRIETARY NASAL MEDICAL TECHNOLOGY PLATFORM

• Rhinomed is a leading medical device company that has developed a proprietary nasal technology platform protected by over 60 patents and 50+ design patents
• We seek to:
• • Socialise 'wearing' a device in the nose in order to solve high value unmet needs in the global consumer health, diagnostic and drug delivery markets
  • Build compelling clinical data that supports both the efficacy and user preference of our technology
  • Ensure people the world over have access to our solutions through the world's premier retail and online pharmacies and drug stores
  • Partner with the world best medical device, diagnostic and pharma companies in order to optimise their solutions

GROUP TRADING PERFORMANCE

RAPID GROWTH ACROSS GLOBAL MARKETS

(f)= forecast figures. All Fy22 figures are presented on an unaudited basis)